How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,081 results for

Sublingual Immunotherapy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Basic science for the clinician: Mechanisms of sublingual and subcutaneous immunotherapy. (PubMed)

Basic science for the clinician: Mechanisms of sublingual and subcutaneous immunotherapy. To discuss the general immunologic changes that occur during immunotherapy, focusing on the differences between subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT).PubMed literature review.Articles pertaining to SCIT and SLIT, with specific emphasis on those that included immune mechanistic studies.Both SCIT and SLIT are characterized by the induction of regulatory B and T cells (...) , decreased allergen-specific T-cell proliferation, a shift from a TH2 to TH1 cytokine milieu and from an IgE to an IgG4/IgA antibody response. These changes are accompanied by clinical improvement in symptoms.Immunotherapy using allergen extracts administered via both subcutaneous and sublingual approaches have demonstrated efficacy in the treatment of allergic rhinoconjunctivitis and other allergic conditions. There are subtle differences between the approaches, and understanding these differences may

Full Text available with Trip Pro

2016 Asthma & Immunology

142. Effect of Japanese cedar-specific sublingual immunotherapy on allergen-specific T<sub>H</sub>2 cell counts in blood. (PubMed)

Effect of Japanese cedar-specific sublingual immunotherapy on allergen-specific TH2 cell counts in blood. The contribution of antigen-specific TH cells in peripheral blood to immunologic mechanisms underlying sublingual immunotherapy (SLIT) remains unclear, partly because of the lack of a standardized method for the analysis of this rare lymphocyte subset.To clarify the role of antigen-specific TH cells during SLIT using a sensitive method analyzing activation marker CD154-positive

2016 Asthma & Immunology

143. Tolerability of an Immunologically Enhanced Subcutaneous Immunotherapy Preparation in Patients Treated with Concomitant Allergy Immunotherapy: A Non-Interventional Observational Study (PubMed)

in patients treated by subcutaneous immunotherapy (SCIT) and concomitant SCIT or sublingual immunotherapy (SLIT) products.In a non-interventional, observational study in Germany treatment of patients with a primary SCIT and concomitant AIT (SCIT or SLIT) was documented during the first 4 months of treatment. Adverse events (AEs) were recorded by the physicians and by patients in diaries, and coded using the Medical Dictionary for Regulatory Activities (MedDRA).Three hundred and seven patients were treated (...) Tolerability of an Immunologically Enhanced Subcutaneous Immunotherapy Preparation in Patients Treated with Concomitant Allergy Immunotherapy: A Non-Interventional Observational Study For causal treatment by allergy immunotherapy (AIT) a single or few allergen products for the clinically most relevant allergens are applied to treat multiple allergies, but few data on the tolerability of multiple AIT applications are available.The aim of our study was to investigate safety and tolerability

Full Text available with Trip Pro

2017 Drugs - real world outcomes

144. Immunotherapy compliance: comparison of subcutaneous versus sublingual immunotherapy. (PubMed)

Immunotherapy compliance: comparison of subcutaneous versus sublingual immunotherapy. Patient compliance is critical for successful allergen immunotherapy (AIT). Previous studies suggest that AIT compliance is worse outside of controlled clinical trials, with reported subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) noncompliance at 11% to 50% and 3% to 25%, respectively.A retrospective review of 384 AIT patients at a single, tertiary care otolaryngic allergy practice

2015 International forum of allergy & rhinology

145. Selection of patients for sublingual immunotherapy (SLIT) versus subcutaneous immunotherapy (SCIT). (PubMed)

Selection of patients for sublingual immunotherapy (SLIT) versus subcutaneous immunotherapy (SCIT). Allergy immunotherapy has been used to help alleviate symptoms of allergic diseases for over 100 years. In the setting of the recently approved sublingual immunotherapy, allergists are now faced with which therapeutic regimen to use in clinical practice, sublingual immunotherapy (SLIT) or subcutaneous immunotherapy (SCIT). Both SLIT and SCIT have been shown to be beneficial for the therapy (...) of seasonal allergic rhinoconjunctivitis. Each therapeutic measure has its associated benefits. SLIT has a better safety profile with less systemic reactions and to date, no reported fatal reactions. SCIT, the primary method of allergen immunotherapy in the United States, has a slightly better efficacy profile and readily allows for treatment of polyallergic patients. This review focuses on how to incorporate SLIT into daily clinical practice and on how to choose SLIT versus SCIT.

2015 Allergy and Asthma Proceedings

146. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. (PubMed)

Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. Allergic rhinitis affects up to 40% of the US population. To desensitize allergic individuals, subcutaneous injection immunotherapy or sublingual immunotherapy may be administered. In the United States, sublingual immunotherapy is not approved by the Food and Drug Administration. However, some US physicians use aqueous allergens, off-label, for sublingual desensitization.To systematically (...) review the effectiveness and safety of aqueous sublingual immunotherapy for allergic rhinoconjunctivitis and asthma.The databases of MEDLINE, EMBASE, LILACS, and the Cochrane Central Register of Controlled Trials were searched through December 22, 2012. English-language randomized controlled trials were included if they compared sublingual immunotherapy with placebo, pharmacotherapy, or other sublingual immunotherapy regimens and reported clinical outcomes. Studies of sublingual immunotherapy

Full Text available with Trip Pro

2013 JAMA

147. Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison (PubMed)

Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison Severe allergic rhinitis uncontrolled by pharmacotherapy can adversely affect quality of life. Both subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) have demonstrated effectiveness in this patient group; however, it remains uncertain which route of administration is more effective.We sought to update existing systematic reviews on the clinical effectiveness

2013 EvidenceUpdates

148. Sublingual immunotherapy reduces symptoms of asthma and hay fever, systematic review finds. (PubMed)

Sublingual immunotherapy reduces symptoms of asthma and hay fever, systematic review finds. 23550050 2013 05 20 2018 10 23 1756-1833 346 2013 Apr 02 BMJ (Clinical research ed.) BMJ Sublingual immunotherapy reduces symptoms of asthma and hay fever, systematic review finds. f2056 10.1136/bmj.f2056 bmj.f2056 Ramsey Sophie S eng News 2013 04 02 England BMJ 8900488 0959-8138 AIM IM Administration, Sublingual Asthma diagnosis drug therapy Humans Immunotherapy methods Review Literature as Topic

2013 BMJ

149. Critical appraisal of the clinical utility of sublingual immunotherapy in allergy (PubMed)

Critical appraisal of the clinical utility of sublingual immunotherapy in allergy Since it was introduced by Noon in 1911, allergen-specific immunotherapy or desensitization has been widely prescribed in the management of allergic diseases. Aimed at the etiology, it represents the only effective treatment for allergy. The basic mechanisms of immunotherapy are becoming better understood and allow us to improve this technique in the future. The sublingual immunotherapy as an alternative (...) to subcutaneous route has been widely studied. Several clinical trials confirmed that sublingual immunotherapy is efficient in reducing allergic respiratory symptoms. The sublingual immunotherapy reduces the risk of developing serious side effects due to desensitization. We performed a literature review in order to remind the mechanisms of action and to demonstrate efficacy and tolerability of the sublingual immunotherapy in the treatment of allergic rhinoconjunctivitis and asthma and its impact

Full Text available with Trip Pro

2016 Contemporary clinical trials communications

150. The Relationship of Pollen Dispersal with Allergy Symptoms and Immunotherapy: Allergen Immunotherapy Improves Symptoms in the Late Period of Japanese Cedar Pollen Dispersal. (PubMed)

The Relationship of Pollen Dispersal with Allergy Symptoms and Immunotherapy: Allergen Immunotherapy Improves Symptoms in the Late Period of Japanese Cedar Pollen Dispersal. The severity of symptoms of pollen-induced allergic rhinitis is affected by the amount of scattered pollen. However, the relationships between the pollen dispersal pattern, symptom severity, and treatment efficacy are not clear.Between 2007 and 2012, we performed 4 randomized, placebo-controlled studies of sublingual (...) immunotherapy (SLIT) on patients with Japanese cedar-induced allergic rhinitis who lived in or around Chiba, Japan. The participants were asked to avoid using rescue medicines during the cedar pollen season as much as possible and to record their nasal symptoms in allergy diaries. The amount of pollen dispersed daily was quantified using the Durham method, and the season was divided into early and late periods based on the pollen count.A total of 721 patients were enrolled in the 4 studies during the 6-year

2018 International Archives of Allergy and Immunology

151. One-year follow-up of clinical and inflammatory parameters in children allergic to grass pollen receiving high-dose ultrarush sublingual immunotherapy. (PubMed)

One-year follow-up of clinical and inflammatory parameters in children allergic to grass pollen receiving high-dose ultrarush sublingual immunotherapy. In a previous double-blind placebo-controlled study, we analyzed a high-dose sublingual immunotherapy (SLIT) ultrarush protocol in asthmatic children monosensitized to grass pollen. In the present open-label study, we assessed the effect of SLIT on symptom score and nonspecific bronchial hyperreactivity in the same cohort followed for 1

2011 Journal of investigational allergology & clinical immunology

152. Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial. (PubMed)

Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial. We previously reported the initial results of the first multicenter, randomized, double-blind, placebo-controlled clinical trial of peanut sublingual immunotherapy (SLIT), observing a favorable safety profile associated with modest clinical and immunologic effects in the first year.We sought to provide long-term (3-year) clinical and immunologic outcomes for our peanut SLIT trial. Key end points

Full Text available with Trip Pro

2015 Journal of Allergy and Clinical Immunology

153. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber. (PubMed)

Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber. The magnitude of effect of sublingual immunotherapy for house dust mite (HDM)-induced allergic rhinitis with or without conjunctivitis is uncertain, partly because there are few well-controlled trials with well-defined doses.We sought to determine the dose-related efficacy and onset of action of the HDM sublingual immunotherapy tablet MK-8237 (Merck/ALK-Abelló) using

2015 Journal of Allergy and Clinical Immunology

154. Safety of sublingual immunotherapy Timothy grass tablet in subjects with allergic rhinitis with or without conjunctivitis and history of asthma. (PubMed)

Safety of sublingual immunotherapy Timothy grass tablet in subjects with allergic rhinitis with or without conjunctivitis and history of asthma. Patients with asthma may be more susceptible to adverse events (AEs) with sublingual immunotherapy tablet (SLIT-tablet) treatment, such as severe systemic reactions and asthma-related events. Using data from eight trials of grass SLIT-tablet in subjects with allergic rhinitis with/without conjunctivitis (AR/C), AE frequencies were determined in adults

2015 Allergy

155. SAFETY AND EFFICACY OF SUBLINGUAL SPECIFIC IMMUNOTHERAPY TO HOUSE DUST MITE USING A DIFFERENT DOSAGE: A PILOT STUDY. (PubMed)

SAFETY AND EFFICACY OF SUBLINGUAL SPECIFIC IMMUNOTHERAPY TO HOUSE DUST MITE USING A DIFFERENT DOSAGE: A PILOT STUDY. The aim of this randomized open study was to evaluate the safety and efficacy of different dosages (2000 UI vs 4000 UI) of sublingual immunotherapy (SLIT) in patients with allergic diseases such as asthma associated to rhinitis and rhinoconjunctivitis sensitized to house dust mites. We enrolled 61 patients with a history of allergic asthma, and a positive skin prick test

2015 Journal of biological regulators and homeostatic agents

156. [Study on the efficacy and safety of sublingual immunotherapy with standardized dermatophagoides farinae drops for allergic rhinitis]. (PubMed)

[Study on the efficacy and safety of sublingual immunotherapy with standardized dermatophagoides farinae drops for allergic rhinitis]. To evaluate the efficacy and safety of the sublingual immunotherapy with dermatophagoides farinae drops on patients with allergic rhinitis.One hundred and twelve cases were collected from adult patients with dust-mite allergic rhinitis of our hospital who could adhere to treatment and regular follow-up. These patients were randomly allocated to receive either (...) sublingual immunotherapy (SLIT group, n = 56) or medical treatment (Control group, n = 56). To evaluate the clinical efficacy by side effects which were registered, symptom and medication scores which were assessed and rhinoconjunctivitis quality of life questionnaire (RQLQ) which was completed in the baseline and two years after treatment.Dropouts after the 2 years' treatment were 5 of SLIT group and 4 of Control group respectively. SLIT group induced the significant reductions on both the symptom

2015 Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery

157. Safety and tolerability of 5-grass pollen tablet sublingual immunotherapy: pooled analysis and clinical review.

Safety and tolerability of 5-grass pollen tablet sublingual immunotherapy: pooled analysis and clinical review. The 5-grass pollen tablet (Oralair®, Stallergenes, Antony, France) is a once-daily preseasonal and coseasonal sublingual immunotherapy (SLIT) that is effective in controlling the symptoms of allergic rhinoconjunctivitis and in reducing the need for symptomatic medication.The body of safety data gathered from the 5-grass pollen tablet clinical development program, post-approval studies (...) pruritus), which are consistent with the sublingual route of administration.The first dose of the 5-grass pollen tablet should be administered under the supervision of an experienced physician, to allow for optimal monitoring and timely management of AEs, should they occur. The 5-grass pollen tablet can be administered at home after the first dose, and patients and carers should be educated on how to manage adverse reactions, unplanned treatment interruptions and situations in which SLIT should

Full Text available with Trip Pro

2015 Expert opinion on drug safety

158. Efficacy and safety of ragweed sublingual immunotherapy in Canadian patients with allergic rhinoconjunctivitis. (PubMed)

Efficacy and safety of ragweed sublingual immunotherapy in Canadian patients with allergic rhinoconjunctivitis. Currently accepted therapies for ragweed allergy in North America consist of pharmacotherapy and subcutaneous allergen immunotherapy injections to treat symptoms. Allergen immunotherapy not only reduces symptoms and the need for pharmacotherapy but has also been shown to have disease-modifying potential. Recently, ragweed immunotherapy administered via sublingual allergen tablet has (...) been approved in North America for treatment of allergic rhinitis with and without conjunctivitis.This was an analysis of pooled data for a prespecified subgroup of Canadian subjects from two multicentre, randomized, double-blind placebo-controlled trials of ragweed sublingual tablet (SLIT-T; 6 and 12 Amb a 1-U of Ambrosia artemisiifolia) in patients aged ≥18y, with ragweed-induced allergic rhinoconjunctivitis (AR/C) with or without asthma. Randomized subjects used once-daily ragweed SLIT-T

Full Text available with Trip Pro

2015 Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology

159. Sublingual grass and ragweed immunotherapy: Clinical considerations-a PRACTALL consensus report. (PubMed)

Sublingual grass and ragweed immunotherapy: Clinical considerations-a PRACTALL consensus report. Sublingual allergen immunotherapy provides a new option for patients with allergic rhinitis in the United States. The efficacy of these sublingual immunotherapy tablets in the treatment of allergic rhinitis has been firmly established in large multicenter clinical trials. In addition, the clinical benefits of sublingual immunotherapy might persist after treatment is discontinued. Local reactions (...) , such as gastrointestinal or oropharyngeal symptoms, are common. However, severe anaphylaxis is rare, and therefore the immunotherapy tablets can be administered at home. Sublingual immunotherapy for allergic rhinitis has been used successfully for years in Europe, and these products might be appropriate for patients who do not do well with standard drug therapy or for those who prefer a disease-modifying approach. Copyright © 2015 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights

2015 Journal of Allergy and Clinical Immunology

160. Smoking effects on quality of life of allergic rhinitis patients after sublingual immunotherapy. (PubMed)

Smoking effects on quality of life of allergic rhinitis patients after sublingual immunotherapy. Although tobacco smoking is of great concern, there is no evidence for the effects of smoking on quality of life (QoL) results after sublingual immunotherapy (SLIT).This study aims tο explore any association between smoking habits (duration and quantity) and QoL results after SLIT in allergic rhinitis (AR).One hundred and sixty three patients following SLIT for AR were participated. SLIT efficacy

2015 Rhinology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>